BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Memento EPFL//
BEGIN:VEVENT
SUMMARY:Target ALS | Consortia Developing New Modalities as Therapeutics f
 or ALS
DTSTART;VALUE=DATE:20241118
DTSTAMP:20260313T051207Z
UID:cc8e43c8909a401208def75d1259393c08e8e8eac39819efd590c290
CATEGORIES:Call for proposal
DESCRIPTION:Aim: Target ALS is a medical research foundation committed to 
 the search for effective treatments for Amyotrophic Lateral Sclerosis (ALS
 )\, also known as Lou Gehrig’s disease. Target ALS funds investigators w
 ho collaborate across scientific disciplines and research constituencies t
 o drive medical breakthroughs for the treatment of ALS.\n\nAdvances in tec
 hnology have allowed for some of the first RNA-directed therapies to come 
 to market to treat CNS disorders. Target ALS is seeking to facilitate dis
 covery and development of the next generation of molecules targeting DNA/R
 NA. The foundation is soliciting proposals from collaborative groups focus
 ed on technological innovation of novel modalities in sporadic and familia
 l forms of ALS.\n\nCollaborative consortia working to optimize drug-like p
 roperties of small and large molecule therapeutics targeting RNA or DNA fo
 r ALS are eligible to apply. Target ALS is particularly interested in supp
 orting projects that propose the study of:\n\n	New antisense oligonucleoti
 de chemistry/design\, siRNA/disiRNA\, CRiSPR\, Zinc Finger\, and similar t
 echnological approaches targeting genetic mutations associated with ALS\n	
 Enhanced brain delivery using conjugation strategies\, lipid nanoparticles
 \, novel capsids\, BBB-penetrant AAV\, or similar platforms\n	Molecules ha
 ving demonstrated cell-based activity but needing additional in vivo valid
 ation of effective delivery to brain and spinal cord\, pharmacodynamic act
 ivity on the target of interest\, and tolerability\n	The novel modality mu
 st be applied to a genetic target associated with ALS\n\nFunding: Max $400
 \,000/year (max. $200\,000 per lab per year)\n\nDuration: 24 months (possi
 ble 12 months in addition based on progress)\n\nEligibility: This call is 
 focused on bringing academic investigators together with other academics o
 r industry partners to work collaboratively on developing the next generat
 ion of gene therapies. Only collaborative projects will be considered.\n\n
 \n	Collaborative projects for this call may comprise groups of 2-4 laborat
 ories synergizing to develop the molecule of interest \n	One industry par
 tner (CRO\, biotech\, pharma) is recommended\n	All collaborators must pro
 vide a copy of the executed agreement between their institutions on data/I
 P sharing OR provide a document that confirms each Technology Transfer Off
 ice has been made aware of the collaborative project and the need to sign 
 a data/IP sharing agreement as part of the full proposal submission. NOT
 E: A fully executed data/IP sharing agreement must be shared within 60 day
 s of notification of award or the grant will be rescinded.\n	A Principal I
 nvestigator can only participate in one LOI submission.\n	Principal Invest
 igators who have two or more active competitive grants from Target ALS are
  not eligible to apply. \n\nHow to Apply: The two-step application proces
 s begins with a Letter of Intent. The letter of intent can be filled in di
 rectly on the application portal. Selected applicants will be notified in 
 January 2025 and invited to submit a full proposal. At the full proposal s
 tage\, a detailed budget is required. Budgets can include researcher salar
 ies and fringe benefits\, materials and consumables\, equipment\, and over
 head of 15%.\n\nDeadline\, Letter of Intent: 18 November 2024\nDeadline\, 
 Full Proposal: 21 February 2024\n\nFurther information\n\n\n	More informat
 ion about the program is available here\n	The application portal can be fo
 und here\n	For any other questions\, please contact the Research Office\n
LOCATION:
STATUS:CONFIRMED
END:VEVENT
END:VCALENDAR